{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:43:36Z","timestamp":1772826216877,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Prostate cancer is the most common cancer in men in the United States with low survival rates once metastasized. Abiraterone is approved for use in castrate\u2010sensitive and castrate\u2010resistant prostate cancer and is used extensively in the Veterans Affairs (VA) healthcare system. Spironolactone, a diuretic used to treat heart failure, edema, ascites, and hypertension, may increase androgen levels and reduce effectiveness of abiraterone when used concurrently to treat prostate cancer patients. While previous case studies support this, no large epidemiology studies have been conducted. The current study utilizes the large, VA prostate cancer data core and evaluates the effect of concomitant spironolactone on efficacy of abiraterone treatment in metastatic prostate cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>The study selected 18,943 veterans with metastatic prostate cancer on abiraterone treatment. Of these, 581 patients (3.1%) were also on concomitant spironolactone. The concomitant treatment group, abiraterone\u2009+\u2009spironolactone, significantly differed from the abiraterone\u2010only group in body mass index, prevalence rates of heart failure and liver disease, and being previously treated with docetaxel. A 1:1 propensity score matching method was used to balance sample sizes and baseline traits between the two treatment groups, abiraterone versus abiraterone\u2009+\u2009spironolactone. Kaplan\u2013Meier curves and Cox proportional hazard model were used to compare 5\u2010year overall survival and all\u2010cause mortality outcomes, respectively, between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After propensity score matched, the abiraterone\u2009+\u2009spironolactone group was treated with abiraterone significantly longer than the abiraterone\u2010only group (mean\u2009\u00b1\u2009standard deviation days 549.0\u2009\u00b1\u2009552.3 vs. 435.5\u2009\u00b1\u2009474.1; <jats:italic>p<\/jats:italic>\u2009=\u20090.0002) and had a higher 5\u2010year overall survival rate (44% vs. 37%; <jats:italic>p<\/jats:italic>\u2009=\u20090.0116). Veterans with metastatic prostate cancer treated with abiraterone\u2009+\u2009spironolactone also had a lower 5\u2010year all\u2010cause mortality compared to those only on abiraterone (hazard ratio 0.80, 95% confidence intervals 0.61\u20130.96; <jats:italic>p<\/jats:italic>\u2009=\u20090.012).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This large VA observational study suggests that concomitant use of spironolactone does not compromise cancer control or survival of metastatic prostate cancer patients treated with abiraterone.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.24811","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T10:13:18Z","timestamp":1730110398000},"page":"148-155","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real\u2010World Retrospective Study"],"prefix":"10.1002","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4950-4405","authenticated-orcid":false,"given":"Erum Z.","family":"Whyne","sequence":"first","affiliation":[{"name":"Research Service, VA North Texas Health Care System Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5753-2935","authenticated-orcid":false,"given":"Haekyung","family":"Jeon\u2010Slaughter","sequence":"additional","affiliation":[{"name":"Research Service, VA North Texas Health Care System Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Kelly","sequence":"additional","affiliation":[{"name":"Pharmacy Service, VA North Texas Health Care system Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Dowell","sequence":"additional","affiliation":[{"name":"VA North Texas Health Care System Dallas Texas USA"},{"name":"Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Prostate Cancer Statistics Centers for Disease Control and Prevention https:\/\/www.cdc.gov\/cancer\/prostate\/statistics\/index.htm."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.7205\/MILMED-D-16-00371"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.21.00030"},{"key":"e_1_2_9_5_1","unstructured":"SEER Cancer Stat Facts: Prostate Cancer. National Cancer Institute. Bethesda MD https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30082-8"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.09.027"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00588-5"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00188-0"},{"issue":"6","key":"e_1_2_9_12_1","first-page":"1","article-title":"Guidelines on the Management of Ascites in Cirrhosis","volume":"55","author":"Moore K. P.","year":"2006","journal-title":"Gut"},{"key":"e_1_2_9_13_1","article-title":"Spironolactone, a Possible Selective Androgen Receptor Modulator, Should Be Used with Caution in Patients with Metastatic Carcinoma of the Prostate","volume":"2012","author":"Sundar S.","year":"2012","journal-title":"Case Reports"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2018.1543827"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.08.006"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","unstructured":"J.Vicente\u2010Valor V.Escudero\u2010Vilaplana R.Collado\u2010Borrell et al. \u201cPotential Negative Pharmacodynamic Interaction of Spironolactone and Abiraterone in Prostate Cancer Patients \u201d Journal of Oncology Pharmacy Practice 28 no. 5 (2022): 1259\u20131263.","DOI":"10.1177\/10781552221074621"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.12.008"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","unstructured":"J. N.GraffandG. D.Huang \u201cLeveraging Veterans Health Administration Clinical and Research Resources to Accelerate Discovery and Testing in Precision Oncology \u201d Federal Practitioner 37 no. Suppl 4 (2020): S62\u2013S67.","DOI":"10.12788\/fp.0028"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-87-4-398"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.24811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T11:31:30Z","timestamp":1734348690000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.24811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/pros.24811"],"URL":"https:\/\/doi.org\/10.1002\/pros.24811","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"2024-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}